	US 11,693,007 B2
	Assay for detection of early stage pancreatic cancer
Ann McNeill Killary, Houston, TX (US); Steven T. Lott, Houston, TX (US); Nanyue Chen, Houston, TX (US); and Seetharaman Balasenthil, Pearland, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 16/488,083
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
PCT Filed Feb. 23, 2018, PCT No. PCT/US2018/019548 § 371(c)(1), (2) Date Aug. 22, 2019, PCT Pub. No. WO2018/156973, PCT Pub. Date Aug. 30, 2018.
Claims priority of provisional application 62/463,348, filed on Feb. 24, 2017.
Prior Publication US 2019/0376976 A1, Dec. 12, 2019
Int. Cl. G01N 33/574 (2006.01)

CPC G01N 33/57438 (2013.01)

15 Claims

1. A method for measuring the expression of the antigens TNC-FN III-C, TFPI, and CA19-9 comprising:

(a) contacting a plurality of antigens in a sample with an anti-TNC-FN III-C antibody, an anti-TFPI antibody, and an anti-CA19-9 antibody to form antigen-antibody complexes; and

(b) detecting the antigen-antibody complexes using detectable moieties that distinctly bind each of the antibodies, thereby measuring the expression of the antigens TNC-FN III-C, TFPI, and CA19-9, wherein an increased expression of the TNC-FN III-C, TFPI, and CA19-9 antigens as compared to a control indicates the presence of pancreatic cancer; and

(c) administering one or more anti-cancer therapies to a subject with increased expression of the TNC-FN III-C TFPI, and CA19-9 antigens as compared to a control sample.